Business Wire

CA-ARMIS

21.11.2023 14:01:37 CET | Business Wire | Press release

Share
Armis Named Platinum Winner of 2023 ‘ASTORS’ Homeland Security Award

Armis, the asset intelligence cybersecurity company, today announced that Armis Centrix™ was named a platinum award winner for Best Vulnerability Management Solution in American Security Today’s 2023 ‘ASTORS’ Awards, the pre-eminent U.S. Homeland Security Awards Program.

“We’re honored to be recognized with this highly coveted award,” said Brian Gumbel, President of Armis. “It’s critical that U.S. government agencies prioritize having a forward-leaning cybersecurity posture to help protect critical public sector assets from malicious attacks of cybercriminals and nation-state actors. Armis is committed to playing a key role in helping government entities to keep critical infrastructure, economies and society safe and secure 24/7.”

Now in its eighth year, the ‘ASTORS’ Awards recognize industry leaders of Physical and Border Security, Cybersecurity, Emergency Preparedness – Management and Response, Law Enforcement, First Responders, as well as federal, state and municipal government agencies in the acknowledgment of their outstanding efforts to Keep our Nation Secure.

The ‘ASTORS’ Homeland Security Awards Program is specifically designed to honor distinguished government and vendor solutions that deliver enhanced value, benefit, and intelligence to end users in a variety of government, homeland security and public safety vertical markets.

“As the nation continues to respond to escalating threats from home and abroad, the innovative solutions being implemented to meet those threats has led to tremendous growth in the field of Homeland Security,” said Michael Madsen, co-founder and publisher of American Security. “Today, the United States is increasingly focusing on protecting IT/cyber security networks and they are calling on innovative companies like Armis to help them do so.”

Every day, federal, state and local governments rely on IT infrastructure to support and power mission critical activities. Continued migration to the cloud, the move to mobile and BYOD, the convergence of IT, OT and IoT, and the sharp increase in remote work have changed how government agencies must approach cybersecurity. It’s essential that these entities no longer depend on conventional perimeter-based defenses to protect critical systems and data.

Armis Centrix™, the cyber exposure management platform, is powered by the Armis AI-driven Asset Intelligence Engine, which sees, protects and manages billions of assets around the world in real time. Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface. With Armis Centrix™ for Vulnerability Prioritization and Remediation, government entities can go beyond vulnerability scanning to address the full cyber risk management lifecycle to consolidate, prioritize and remediate all vulnerabilities based on potential risk to the organization.

Armis Centrix™ is FedRAMP moderate and DoD IL4 authorized. Learn more about Armis’ work in the public sector here: https://www.armis.com/cybersecurity/federal-government/

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

About American Security Today

American Security Today (AST), the ‘New Face in Homeland Security™’, is the premier digital media platform in the U.S. Homeland Security and Public Safety Industry, focused on breaking news and in-depth coverage of the newest initiatives and hottest technologies in physical & IT security on the market today.

AST highlights the most cutting-edge and forward-thinking security solutions across a wide variety of media products delivered weekly, and monthly to over 75,000 qualified government and security industry readers, essential to meeting today’s growing security challenges to ‘Secure our Nation, One City at a Time™’.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231121230265/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye